3rd Quarter - Report

W STRATEGIES, LLC for ALEXION PHARMACEUTICALS

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

H.R. 1314: Trade Preferences Extension Act as it relates to access to orphan drug therapies.

LobbyistCovered position, as disclosed
DARREN WILLCOX —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1314 (114th)

Copyright/Patent/Trademark CPT

H.R. 9: Innovation Act, including proposed changes to the Inter Partes Review (IPR) process at the Patent and Trademark Office (PTO).

LobbyistCovered position, as disclosed
DARREN WILLCOX —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 9 (114th)

Health Issues HCR

Implementation of Affordable Care Act as it relates to a regulatory pathway for biosimilars. H.R. 6: 21st Century Cures Act. Education about the value of innovative new medicines.

LobbyistCovered position, as disclosed
DARREN WILLCOX —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 6 (114th)

Medicare/Medicaid MMM

Educated staff about access to therapies for rare diseases. Education about reimbursement for orphan drug therapies in skilled nursing facilities and proposed add-on payments in inpatient hospitals.

LobbyistCovered position, as disclosed
DARREN WILLCOX —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.